Table 3.
Intention to treat data for infliximab, etanercept and adalimumab
| Week 0 | Week 2 | Week 6 | Week 12 | Week 24 | Year 1 | Year 2 | Year 3 | ||
|---|---|---|---|---|---|---|---|---|---|
| Disease measure | Drug | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| BASDAI 50 | Infliximab [24,93-95] | 0 | 41 | ~58 | 53 | 47 | 41 | 47 | |
| Etanercept [25] | 0 | 57 | 71 | ||||||
| Adalimumab [13] | 0 | 43 | 51 | 56 | 59 | ||||
| ASAS 20 | Infliximab [37,71] | 0 | ~50 | ~61 | ~62 | ~61 | 74 | ||
| Etanercept [96,97] | 0 | 53 | 60 | ~76 | 83 | ||||
| Adalimumab [10,13] | 0 | ~42 | ~56 | 58 | 65 | 65 | |||
| ASAS 40 | Infliximab [93,95] | 0 | ~32 | 50 | 47 | ~54 | 52 | 50 | |
| Etanercept [97] | 0 | 49 | ~64 | ~62 | ~66 | ||||
| Adalimumab [13] | 0 | ~35 | 46 | 51 | |||||
| ASAS 5/6 | Infliximab [93] | 0 | ~34 | ~63 | ~52 | 53 | ~48 | 46 | |
| Etanercepta [98] | 0 | ~50 | ~69 | ~60 | 65 | ||||
| Adalimumab [13] | 0 | ~37 | 48 | 59 | ~55 | 59 | |||
| ASAS Partial Remission | Infliximab [71] | 0 | ~10 | ~17 | ~21 | 22 | ~23 | ~29 | |
| Etanercepta [98] | 0 | 31 | 31 | ~27 | 31 | ||||
| Adalimumab [13] | 0 | ~20 | 21 | 24 | 34 |
Intention-to-treat data from randomised control trials and open-label extensions based on duration of anti-TNF therapy for infliximab, etanercept and adalimumab. ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. aEtanercept ASAS 5/6 and partial remission intention-to-treat data are from patients recommencing etanercept after withdrawing for several months after a 6-month randomised control trial with etanercept.